Description
What is Xadago (safinamide) for?
Xadago (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor, indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes[2].
How does Xadago (safinamide) work?
Parkinson’s disease develops when neurons (brain cells) in a particular part of the brain stop working properly and are lost over time.
These neurons produce an important chemical called dopamine. Dopamine is used by the brain to send messages across brain areas to help control movement. Eventually, the brain cannot make enough dopamine to control the movement properly. There is currently no cure for Parkinson’s Disease. Existing treatments aim to help patients manage symptoms.[4]
The active substance in Xadago – safinamide – blocks the enzyme MAO-B which breaks down dopamine, thereby helping to restore dopamine levels in the brain and improving the patient’s symptoms[5].
Where has Xadago (safinamide) been approved?
Xadago (safinamide) was approved as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes by:
Food and Drug Administration (FDA), USA, March 21, 2017[1]
European Medical Agency (EMA), European Union, February 24, 2017[5]
Therapeutic Goods Administration (TGA), Australia, November 2, 2018[6]
Health Canada (as Onstryv), January 9, 2019[7]
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.
Please be aware that any decision to use a prescription generic or brand name medicine should always be taken in consultation with a medical professional. The FDA has sent warning letters to drugmakers in India concerning the quality of their medicines.
How is Xadago (safinamide) taken?
The standard dosage is[2,3]
Start dose: 50 mg tablets once daily at the same time of day
After two weeks, the dose may be increased to 100 mg once daily, based on individual’s need and tolerability
Reviews
There are no reviews yet.